EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

The Aspirin Conundrum—Navigating Negative Results, Age, Aging Dynamics, and Equity

Jeanne S Mandelblatt, Candace Mainor, Barry I Hudson

JAMA · 2024

DOI: 10.1001/jama.2024.4828 ↗

Kurz gefasst

Editorial in der Zeitschrift JAMA, 2024. Verfasst von Jeanne S Mandelblatt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown Lombardi Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Washington, DC. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Alliance trial led by Chen and colleagues 1 and published in this issue of JAMA addresses an important topic in the management of breast cancer: can daily use of 300 mg of aspirin improve invasive disease-free survival among persons with a diagnosis of nonmetastatic, high-risk breast cancer?The answer is a fairly definitive no based on prespecified futility rules in a rigorous phase 3, randomized, placebo-controlled, doubleblind trial.The trial (A011502) enrolled 3020 persons (3004 women [99.5%] and 16 men [0.5%]) from 534 academic and community sites across the US and Canada.Although the trial was planned for 5 years, it was suspended at the first interim safety analysis (median follow-up, 33.8 months; range, 0.1-72.6)because the results indicated futility: 141 vs 112 invasive disease-free events in the aspirin vs placebo group, respectively (hazard ratio, 1.27; 95% CI, 0.99-1.63;P = .06).Despite the negative result, this trial was commendable for including clinically important stratifications, prespecified subgroup analyses, rigorous safety monitoring, and stakeholder engagement.Although these specific trial results may be most interesting to breast oncologists, several of the critical issues raised by this trial have broad implications for modern cancer and other disease intervention trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinBreast NeoplasmsAnti-Inflammatory Agents, Non-SteroidalAgedHumansAge FactorsAgingUnited States

Substanzen

AspirinAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Georgetown Lombardi Institute for Cancer and Aging Research, Lombardi Comprehensive Cancer Center, Washington, DC.
  • Departments of Oncology and Medicine, Georgetown University Medical Center, Georgetown University, Washington, DC.
  • Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University and MedStar Health, MedStar-Georgetown University Hospital, Washington, DC.
  • Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC.

Förderung

  • NIA NIH HHS
  • NCI NIH HHS

Zitieren

APA

Mandelblatt, J. S., Mainor, C., & Hudson, B. I. (2024). The Aspirin Conundrum—Navigating Negative Results, Age, Aging Dynamics, and Equity. JAMA. https://doi.org/10.1001/jama.2024.4828

Vancouver

Mandelblatt JS, Mainor C, Hudson BI. The Aspirin Conundrum—Navigating Negative Results, Age, Aging Dynamics, and Equity. JAMA. 2024. doi:10.1001/jama.2024.4828

BibTeX
@article{Mandelblatt2024,
  author = {Mandelblatt, Jeanne S and Mainor, Candace and Hudson, Barry I},
  title = {The Aspirin Conundrum—Navigating Negative Results, Age, Aging Dynamics, and Equity},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.4828}
}
Kostenlos starten →